(PNTG) Pennant - Overview
Stock: Home Health, Hospice, Senior Living
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 38.3% |
| Relative Tail Risk | -4.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.37 |
| Alpha | -2.89 |
| Character TTM | |
|---|---|
| Beta | 0.506 |
| Beta Downside | 0.339 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.16% |
| CAGR/Max DD | 0.90 |
Description: PNTG Pennant January 25, 2026
The Pennant Group, Inc. (NASDAQ:PNTG) is a U.S.-based provider of integrated healthcare services, operating two primary segments: Home Health & Hospice Services and Senior Living Services. Its portfolio includes clinical home-health care (nursing, therapy, medical social work, aide services), hospice care covering physical, spiritual, and psychosocial support, and senior-living communities that deliver housing, meals, activities, and assistance with daily living.
Geographically, Pennant runs agencies and senior-living facilities across 13 states in the western and central United States, including Arizona, California, Texas, and Washington. The company’s recent FY 2024 filing shows total revenue of approximately $210 million, a 12 % year-over-year increase, with the Home Health segment contributing roughly 55 % of that revenue. Senior-living occupancy averaged 92 % in Q4 2024, indicating strong demand in its target markets.
Industry-wide, the home-health market is projected to grow at a 6 % compound annual growth rate through 2028, driven by the aging Baby-Boom cohort and expanding Medicare Advantage enrollment. However, reimbursement pressure remains a risk; recent CMS policy changes trimmed hospice per-patient-day rates by 3 % in 2024, which could compress margins if not offset by volume growth.
For a deeper dive into PNTG’s valuation metrics, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 26.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 2.49 > 1.0 |
| NWC/Revenue: 0.55% < 20% (prev 1.72%; Δ -1.17% < -1%) |
| CFO/TA 0.06 > 3% & CFO 47.9m > Net Income 26.7m |
| Net Debt (300.5m) to EBITDA (52.0m): 5.77 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.3m) vs 12m ago 12.46% < -2% |
| Gross Margin: 15.44% > 18% (prev 0.13%; Δ 1531 % > 0.5%) |
| Asset Turnover: 121.0% > 50% (prev 100.9%; Δ 20.15% > 0%) |
| Interest Coverage Ratio: 10.81 > 6 (EBITDA TTM 52.0m / Interest Expense TTM 4.08m) |
Altman Z'' 1.00
| A: 0.01 (Total Current Assets 114.0m - Total Current Liabilities 109.4m) / Total Assets 753.6m |
| B: 0.10 (Retained Earnings 78.2m / Total Assets 753.6m) |
| C: 0.06 (EBIT TTM 44.0m / Avg Total Assets 700.2m) |
| D: 0.19 (Book Value of Equity 78.2m / Total Liabilities 410.6m) |
| Altman-Z'' Score: 1.00 = BB |
Beneish M -2.99
| DSRI: 0.88 (Receivables 96.1m/84.0m, Revenue 847.3m/652.3m) |
| GMI: 0.87 (GM 15.44% / 13.41%) |
| AQI: 1.12 (AQ_t 0.41 / AQ_t-1 0.37) |
| SGI: 1.30 (Revenue 847.3m / 652.3m) |
| TATA: -0.03 (NI 26.7m - CFO 47.9m) / TA 753.6m) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of PNTG shares?
Over the past week, the price has changed by +9.88%, over one month by +6.16%, over three months by +27.79% and over the past year by +11.50%.
Is PNTG a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PNTG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 37.5 | 23.6% |
| Analysts Target Price | 37.5 | 23.6% |
| ValueRay Target Price | 31.3 | 3.2% |
PNTG Fundamental Data Overview February 03, 2026
P/E Forward = 21.5517
P/S = 1.1277
P/B = 2.9671
P/EG = 1.6593
Revenue TTM = 847.3m USD
EBIT TTM = 44.0m USD
EBITDA TTM = 52.0m USD
Long Term Debt = 26.0m USD (from longTermDebt, last quarter)
Short Term Debt = 22.0m USD (from shortTermDebt, last quarter)
Debt = 302.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 300.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.26b USD (955.5m + Debt 302.8m - CCE 2.34m)
Interest Coverage Ratio = 10.81 (Ebit TTM 44.0m / Interest Expense TTM 4.08m)
EV/FCF = 34.79x (Enterprise Value 1.26b / FCF TTM 36.1m)
FCF Yield = 2.87% (FCF TTM 36.1m / Enterprise Value 1.26b)
FCF Margin = 4.26% (FCF TTM 36.1m / Revenue TTM 847.3m)
Net Margin = 3.15% (Net Income TTM 26.7m / Revenue TTM 847.3m)
Gross Margin = 15.44% ((Revenue TTM 847.3m - Cost of Revenue TTM 716.4m) / Revenue TTM)
Gross Margin QoQ = 20.16% (prev 13.80%)
Tobins Q-Ratio = 1.67 (Enterprise Value 1.26b / Total Assets 753.6m)
Interest Expense / Debt = 0.34% (Interest Expense 1.02m / Debt 302.8m)
Taxrate = 26.78% (2.52m / 9.40m)
NOPAT = 32.2m (EBIT 44.0m * (1 - 26.78%))
Current Ratio = 1.04 (Total Current Assets 114.0m / Total Current Liabilities 109.4m)
Debt / Equity = 0.94 (Debt 302.8m / totalStockholderEquity, last quarter 321.9m)
Debt / EBITDA = 5.77 (Net Debt 300.5m / EBITDA 52.0m)
Debt / FCF = 8.32 (Net Debt 300.5m / FCF TTM 36.1m)
Total Stockholder Equity = 308.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.81% (Net Income 26.7m / Total Assets 753.6m)
RoE = 8.67% (Net Income TTM 26.7m / Total Stockholder Equity 308.0m)
RoCE = 13.18% (EBIT 44.0m / Capital Employed (Equity 308.0m + L.T.Debt 26.0m))
RoIC = 9.57% (NOPAT 32.2m / Invested Capital 336.9m)
WACC = 5.97% (E(955.5m)/V(1.26b) * Re(7.78%) + D(302.8m)/V(1.26b) * Rd(0.34%) * (1-Tc(0.27)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 8.00%
[DCF Debug] Terminal Value 83.88% ; FCFF base≈27.6m ; Y1≈22.8m ; Y5≈16.5m
Fair Price DCF = 5.60 (EV 494.1m - Net Debt 300.5m = Equity 193.6m / Shares 34.6m; r=5.97% [WACC]; 5y FCF grow -20.90% → 2.90% )
EPS Correlation: 92.13 | EPS CAGR: 47.41% | SUE: 0.34 | # QB: 0
Revenue Correlation: 98.67 | Revenue CAGR: 21.09% | SUE: 1.63 | # QB: 6
EPS next Quarter (2026-03-31): EPS=0.30 | Chg30d=-0.004 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=1.31 | Chg30d=-0.001 | Revisions Net=+0 | Growth EPS=+13.9% | Growth Revenue=+24.1%